Literature DB >> 10854757

Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.

M Quik1, S Police, L He, D A Di Monte, J W Langston.   

Abstract

D(3) receptors are prominently localized in the primate caudate-putamen, and D(3) receptor agonist properties may offer an advantage in Parkinson's disease therapy. In the present experiments, we investigated the relationship between D(3) receptor mRNA, D(3) receptor sites and the dopamine transporter in monkey basal ganglia by comparing their distribution in the brain of control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys (Samirai sciureus). In control monkeys, D(3) receptor mRNA appears to be widely expressed throughout the brain, with a distribution similar to that observed in both man and rodent. D(3) receptors are present in areas which express mRNA but also in some which do not, an observation which suggests they may be both pre- and postsynaptic in the monkey brain. Chronic MPTP administration, which selectively destroys the nigrostriatal system, resulted in a 70 to 99% depletion of the dopamine transporter in the basal ganglia. Autoradiographic analysis showed that after MPTP treatment there was a significant decline in D(3) receptors in the caudate, but not putamen, globus pallidus, substantia nigra or other dopaminergic regions. D(3) receptor mRNA expression was not changed in any region after nigrostriatal lesioning. Two weeks of L-3,4-dihydroxyphenylalanine (levodopa, L-DOPA) treatment, which alleviated Parkinsonism but also induced dyskinesias, reversed the MPTP-induced decline in caudate D(3) receptors. These results show that there is a selective decline in D(3) receptors in the caudate after nigrostriatal degeneration, which is reversed by L-DOPA treatment. Since the majority of dopaminergic nerve terminals were destroyed after MPTP lesioning, the reversal in D(3) receptors after L-DOPA treatment may represent an increase in caudate postsynaptic receptors, which could conceivably contribute to an imbalance in striatal circuitry and the development of dyskinesias.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854757     DOI: 10.1016/s0306-4522(00)00130-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  24 in total

Review 1.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

2.  Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Authors:  Isabelle Boileau; Doris Payer; Sylvain Houle; Arian Behzadi; Pablo M Rusjan; Junchao Tong; Diana Wilkins; Peter Selby; Tony P George; Martin Zack; Yoshiaki Furukawa; Tina McCluskey; Alan A Wilson; Stephen J Kish
Journal:  J Neurosci       Date:  2012-01-25       Impact factor: 6.167

3.  [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.

Authors:  Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

4.  Dopamine D(3) receptors are down-regulated following heterologous endocytosis by a specific interaction with G protein-coupled receptor-associated sorting protein-1.

Authors:  Dawn Thompson; Jennifer L Whistler
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

5.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

6.  Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys.

Authors:  Adriana Galvan; Xing Hu; Karen S Rommelfanger; Jean-Francois Pare; Zafar U Khan; Yoland Smith; Thomas Wichmann
Journal:  J Neurophysiol       Date:  2014-04-23       Impact factor: 2.714

7.  Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey.

Authors:  M Quik; Y Polonskaya; J M Kulak; J M McIntosh
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

8.  D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.

Authors:  Doris E Payer; Mark Guttman; Stephen J Kish; Junchao Tong; John R Adams; Pablo Rusjan; Sylvain Houle; Yoshiaki Furukawa; Alan A Wilson; Isabelle Boileau
Journal:  Neurology       Date:  2015-12-30       Impact factor: 9.910

9.  Synthesis and initial evaluation of [11C](R)-RWAY in monkey-a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET.

Authors:  Julie A McCarron; Sami S Zoghbi; H Umesha Shetty; Eric S Vermeulen; Håkan V Wikström; Masanori Ichise; Fumihiko Yasuno; Christer Halldin; Robert B Innis; Victor W Pike
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

10.  Extrastriatal dopaminergic circuits of the Basal Ganglia.

Authors:  Karen S Rommelfanger; Thomas Wichmann
Journal:  Front Neuroanat       Date:  2010-10-27       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.